Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0EUGGJ
ADC Name	ICAM1-DM1 ADC
Synonyms	ICAM1-DM1 ADC (Boston Children's Hospital); anti-ICAM1-SMCC-DM1 (Boston Children's Hospital) Click to Show/Hide
Organization	Boston Children's Hospital
Drug Status	Clinical candidate
Indication	In total 1 Indication(s) Pancreatic cancer [ICD11:2C10] Clinical candidate
Drug-to-Antibody Ratio	3.8
Structure
	3D MOL	2D MOL
Antibody Name	Anti-ICAM1 mAb		Antibody Info
Antigen Name	Intercellular adhesion molecule 1 (ICAM1)		Antigen Info
Payload Name	Mertansine DM1		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)		Linker Info
Conjugate Type	The succinimide of SMCC randomly reacts with the free amino groups of lysine residues in mab, forming a stable amide bond.
Combination Type	Emtansine

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	4	nM	BxPC-3 cells	Pancreatic ductal adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	9.8	nM	PANC-1 cells	Pancreatic ductal adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	> 100	nM	hTERT-HPNE cells	Normal

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 nM	Positive ICAM1 expression (ICAM1+++/++)
Method Description	Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted Tras-Me-PRX (10 mg/mL antibody) for 24 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.80 nM	Positive ICAM1 expression (ICAM1+++/++)
Method Description	Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted Tras-Me-PRX (10 mg/mL antibody) for 24 h.
In Vitro Model	Pancreatic ductal adenocarcinoma	PANC-1 cells		CVCL_0480
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100 nM	Positive ICAM1 expression (ICAM1+++/++)
Method Description	Cells were plated in 96-well tissue culture plates (SigmaAldrich) 1 day before treatment, serum-starved, and treated with serially diluted Tras-Me-PRX (10 mg/mL antibody) for 24 h.
In Vitro Model	Normal	hTERT-HPNE cells		CVCL_C466

References

Ref 1	A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer. Adv Sci (Weinh). 2020 Nov 3;7(24):2002852. doi: 10.1002/advs.202002852.